Therapeutic Targeting of microRNAs in Cancer: Future Perspectives

62Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Preclinical Research The discovery of microRNAs (miRNAs) and their link with cancer has opened a new era in cancer therapeutics. Approximately, 18-24 nucleotides long, miRNAs can up-regulate or down-regulate gene expression in many cancer types and are respectively categorized as oncogenes (oncomirs) or tumor suppressors. Expression profiles of miRNAs with biomarker potential can be used for the classification, diagnosis, therapeutic treatment, and prognosis of different cancer types. miRNA mimics and miRNA antagonists are the two main approaches to miRNA-based cancer therapies that respectively inhibit oncomirs or restore the expression of tumor suppressive miRNAs. This review serves to provide some general insight into miRNA biogenesis, cancer related miRNAs, and miRNA therapeutics.

Cite

CITATION STYLE

APA

Tutar, L., Tutar, E., Özgür, A., & Tutar, Y. (2015, November 1). Therapeutic Targeting of microRNAs in Cancer: Future Perspectives. Drug Development Research. Wiley-Liss Inc. https://doi.org/10.1002/ddr.21273

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free